Linc
VC Fund
Stockholm, Sweden
Linc is a VC fund in Stockholm focused on Biotechnology and Health Care. Linc AB invests in product oriented companies in the Nordic Life Science industry. Linc AB mainly invest in and develop small and medium-sized product oriented life science companies in Medical Technology and Pharmaceuticals.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries Linc invests in
Stages Linc invests in
Countries Linc invests in
Investment Focus
Industry
- Biotechnology 6 (50%)
- Health Care 5 (42%)
- Pharmaceutical 5 (42%)
- Clinical Trials 2 (17%)
- Medical 1 (8%)
Stage
- Post-IPO Equity 3 (25%)
- Venture - Series Unknown 3 (25%)
- Post-IPO Debt 2 (17%)
- Series B 1 (8%)
- Series C 1 (8%)
Country
- Sweden 7 (58%)
- Denmark 2 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Egetis Therapeutics
|
Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development. | $38.3M / Post-IPO Equity / Apr 21, 2026 | |
OncoZenge
|
OncoZenge is a Swedish pharmaceutical company. It develops better products for the supportive care of cancer patients. | $789.6K / Post-IPO Debt / Jul 09, 2025 | |
Oncorena
|
Oncorena treatment for renal cancer | $14M / Venture - Series Unknown / Jun 26, 2025 | |
OssDsign
|
OssDsign was founded in May 2011 by Professor Håkan Engqvist, Dr Thomas Engstrand, Bo Qwarnstrom, Jonas Åberg, Uppsala University AB and other leading clinical, preclinical and materials researchers and engineers. The key people in the company are presented below. OssDsign has in addition developed a network of international experts in ClinicalAffairs, Regulatory and Business Development. | $16.4M / Post-IPO Equity / Jun 03, 2025 | |
Gesynta Pharma
|
Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se | $27.6M / Series B / Jan 20, 2025 | |
Medivir
|
Medivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology. Medivir is a protease inhibitor design and the nucleotide/nucleoside science and we are dedicated to developing innovative pharmaceuticals that meet a great unmet medical need. Our commercial organization provides a portfolio ofspecialty care, pharmaceuticals on the Nordic market. | $2.8M / Post-IPO Debt / Oct 24, 2024 | |
Cinclus Pharma
|
Cinclus Pharma AG is a research based biotech company developing small molecules for the treatment of gastric acid related diseases. Their main asset, X842, has been studied in a Phase I clinical trial. Cinclus Pharma is based in Basel, Switzerland. | $24.1M / Venture - Series Unknown / May 20, 2022 | |
Initiator Pharma
|
Initiator Pharma is a Biotech company established in Aarhus, Denmark. Its main asset IPED2015 represents a novel treatment paradigm for the treatment of Erectile Dysfunction (ED) and will improve the quality of life for the growing number for patients (and their partners) that do not respond or cannot be treated with the current marketedmedication. | $2.1M / Secondary Market / Apr 13, 2022 | |
FluoGuide
|
FluoGuide provides solutions for maximizing surgical outcome through intelligent targeting. FluoGuide develops surgical solutions that are expected to reduce suffering for the patient and increase the likelihood of cure as well as reducing costs for the health care system. | $25.9M / Post-IPO Equity / Mar 10, 2022 | |
|
Oncorena
|
Oncorena treatment for renal cancer | $7.3M / Venture - Series Unknown / Dec 23, 2021 | |
| See all 12 investments → | |||
Co-Investors
Hadean Ventures
3 deals together
Industrifonden
3 deals together
Adrigo Asset Management
2 deals together
HealthCap
2 deals together
Amboy Street Ventures
1 deal together
Arbejdernes Landsbank
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Linc invest in?
Linc invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Post-IPO Equity and Venture - Series Unknown stage. Most of the 12 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Linc last invest?
The most recent investment recorded for Linc closed in Apr 2026. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
